louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02848183: Optimal Treatment Strategy Based on for Pediatric AML
Official title: Optimal Treatment Strategy Based on Prognostic Groups for Pediatric de Novo Acute Myeloid Leukemia
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Pediatric Acute Myeloid Leukemia
Lead sponsor: Samsung Medical Center
Sponsor class: OTHER
First posted: 2016-07-28
Enrollment: 350
Sex: ALL
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to optimize therapy according to the known risk factors and treatment response in pediatric acute myeloid leukemia (AML)

Detailed description: I. Risk group assessment Favorable prognosis group: Low risk features + Good response

Intermediate prognosis group:

1. Low risk features + Delayed response-1
2. Standard risk features + Good response
3. Standard risk features + Delayed response-1

Poor prognosis group:

1. Any high risk features irrespective of treatment response
2. Any delayed response-2 irrespective of risk features
3. Any refractory state irrespective of risk features
4. Any early relapse

II. Chemotherapy Induction-1: Cytarabine + idarubicin Induction-2: High dose (HD) cytarabine + mitoxantrone Consolidation-1: Cytarabine + idarubicin Consolidation-2: HD cytarabine + etoposide Consolidation-3: HD cytarabine + mitoxantrone Consolidation-4: HD cytarabine + etoposide

III. Allogeneic hematopoietic stem cell transplantation (HSCT) Favorable prognosis group: chemotherapy only Intermediate prognosis group: chemotherapy or HSCT with reduced intensity conditioning Poor prognosis group: HSCT with myeloablative conditioning

Eligibility criteria: Inclusion Criteria:

* Patients who were newly diagnosed with de novo AML
* Patients who had recurrent cytogenetic abnormalities of AML even though the bone marrow blast percent is lower than 20%

Exclusion Criteria:

* Acute promyelocytic leukemia
* Down syndrome AML
* Therapy-related AML
* AML developed from myelodysplastic syndrome or other marrow failure syndrome
* Isolated myeloid sarcoma without bone marrow involvement
* Patients who cannot undergo chemotherapy as scheduled due to serious complications at diagnosis

Primary outcomes:
measure: Rate of event free survival
timeFrame: Up to 5 years
Secondary outcomes:
measure: Proportion of patients who achieved complete remission
timeFrame: Up to 3 months
Other outcomes:
Locations:
city: Chonnam
country: Korea, Republic of
facility: Chonnam National University Hwasun Hospital
city: Seoul
country: Korea, Republic of
facility: Samsung Medical Center
city: Seoul
country: Korea, Republic of
facility: St. Mary Hospital
Study officials:
References:
Clinical trial NCT03602183: Pediatric Intubation During Emergency Conditions
Official title: A Comparison of Direct vs. Video-laryngoscopes for Different Emergency Pediatric Airway Scenarios
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Endotracheal Intubation
Pediatric
Cardiac Arrest
Injuries
Keywords: difficult airway
endotracheal intubation
chest compression
physician
Lead sponsor: Lazarski University
Sponsor class: OTHER
Collaborators: name: Wroclaw Medical University
name: The Cleveland Clinic
name: Medical University of Vienna
First posted: 2018-07-26
Enrollment: 83
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The effectiveness of endotracheal intubation in pre-hospital conditions is insufficient - especially in the context of pediatric patients. Anatomical differences in pediatric patients compared to adults: a relative larger tongue, a larger and more flabby epiglottis - located more cephalously - that make intubation is more difficult than for adults. Also, higher oxygen metabolism requires the immediate response of medical personnel to children in case of need to protect the airways and support breath.


Eligibility criteria: Inclusion Criteria:

* paramedics
* give voluntary consent to participate in the study
* none experience in videolaryngoscopy
* less than 1 year experience in medicine

Exclusion Criteria:

* not meet the above criteria
* wrist or low back diseases

Primary outcomes:
measure: Intubation time
timeFrame: 1 day
Secondary outcomes:
measure: Success of intubation
timeFrame: 1 day
measure: Cormack-Lehane grading
timeFrame: 1 day
measure: POGO score - percentage of glottic opening
timeFrame: 1 day
measure: Preferred ETI device
timeFrame: 1 day
measure: Ease of use
timeFrame: 1 day
Other outcomes:
Locations:
city: Warsaw
country: Poland
facility: Lazarsku University
state: Masovian
Study officials:
affiliation: Lazarski University
name: Lukasz Szarpak, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Szarpak L, Karczewska K, Czyzewski L, Truszewski Z, Kurowski A. Airtraq Laryngoscope Versus the Conventional Macintosh Laryngoscope During Pediatric Intubation Performed by Nurses: A Randomized Crossover Manikin Study With Three Airway Scenarios. Pediatr Emerg Care. 2017 Nov;33(11):735-739. doi: 10.1097/PEC.0000000000000741.
citation: Madziala M, Smereka J, Dabrowski M, Leung S, Ruetzler K, Szarpak L. A comparison of McGrath MAC(R) and standard direct laryngoscopy in simulated immobilized cervical spine pediatric intubation: a manikin study. Eur J Pediatr. 2017 Jun;176(6):779-786. doi: 10.1007/s00431-017-2909-9. Epub 2017 Apr 21.
citation: Szarpak L, Kurowski A, Czyzewski L, Rodriguez-Nunez A. Video rigid flexing laryngoscope (RIFL) vs Miller laryngoscope for tracheal intubation during pediatric resuscitation by paramedics: a simulation study. Am J Emerg Med. 2015 Aug;33(8):1019-24. doi: 10.1016/j.ajem.2015.04.054. Epub 2015 Apr 30.
Clinical trial NCT01147783: Airway Anatomy of the SimBaby
Official title: A Comparison of Pediatric Airway Anatomy With the SimBaby High-Fidelity Simulator
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Airway Reality
Lead sponsor: Medical University of Vienna
Sponsor class: OTHER
First posted: 2010-06-22
Enrollment: 20
Sex: ALL
Minimum age (years): 1
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: infants undergoing routine head MRI

Brief summary: The aim of the present study is to compare radiographic upper airway measurements of the SimBabyTM pediatric patient high-fidelity simulator with actual human airway anatomy to assess the grade of realism of the simulator.


Eligibility criteria: Inclusion Criteria:

* MRI or CT head or neck including upper airway
* age: 1-12 months

Exclusion Criteria:

* no pathology of airway, face, neck
* no airway device in place
* head not in neutral position
* neck collar

Primary outcomes:
measure: pharyngeal measurements
Secondary outcomes:
measure: anatomic structures of the upper airway
Other outcomes:
Locations:
city: Vienna
country: Austria
facility: Medical University of vienna
Study officials:
affiliation: Medical University of Vienna, Dept. of. Anesthesia, General Intensive Care and Pain Management
name: Oliver Kimberger, M.D., P.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Schebesta K, Hupfl M, Ringl H, Machata AM, Chiari A, Kimberger O. A comparison of paediatric airway anatomy with the SimBaby high-fidelity patient simulator. Resuscitation. 2011 Apr;82(4):468-72. doi: 10.1016/j.resuscitation.2010.12.001. Epub 2011 Jan 14.
Clinical trial NCT06677983: Clinical Performance and Acceptance of Bioflx Crowns
Official title: Clinical Performance and Acceptance of Bioflx Crowns: a Randomized Controlled Clinical Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Caries
Lead sponsor: Alexandria University
Sponsor class: OTHER
First posted: 2024-11-07
Enrollment: 62
Sex: ALL
Minimum age (years): 4
Maximum age (years): 8
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Treating pediatric patients with early childhood caries can be challenging. For clinicians, managing a young child while ensuring high-quality treatment is difficult. It is essential to have the best equipment and materials available. Today, aesthetics are crucial in managing decayed teeth, with zirconia crowns often preferred for their visual appeal, although they require substantial preparation. The newly developed Bioflx crown, combining stainless steel and zirconia properties, offers an alternative solution.


Eligibility criteria: Inclusion Criteria:

* A child with primary molars is indicated for full coverage.

Exclusion Criteria:

* Children with any systemic disease
* Clinical or radiographic signs/symptoms of irreversible pulpitis as abscess, fistula, spontaneous pain, mobility, furcation involvement, internal or external root resorption
* Children cooperation (1,2) according to Frankl scale
* Parents are unwilling to enroll their children in study

Primary outcomes:
measure: Change in clinical success
timeFrame: baseline, 6 months, and 12 months
measure: parental satisfaction
timeFrame: through study completion, an average of 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Alexandria
country: Egypt
facility: Outpatient Clinic of Pediatric dentistry, Faculty of dentistry, pharos University, Egypt
Study officials:
References:
Clinical trial NCT04129697: Intratympanic Steroids for Sudden Hearing Loss
Official title: Intratympanic Dexamethasone or Methylprednisolone for Sudden Hearing Loss as a Salvage Treatment: a Randomized, Double-blind, Multi-center Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Dexamethasone or Methylprednisolone; Sudden Hearing Loss; Intratympanic Steroid
Lead sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Sponsor class: OTHER
First posted: 2019-10-17
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: For patients with sudden hearing loss, the initial treatment is not usually effective. We use Dexamethasone or Methylprednisolone to be an Intratympanic steroid administration as a salvage treatment. An randomized, double-blind, multi-center study is designed to find the difference between Dexamethasone or Methylprednisolone.


Eligibility criteria: Inclusion Criteria:

sudden hearing loss and initial treatment is not effective

Exclusion Criteria:

the patients refused intratympanic steroids treatment.

Primary outcomes:
measure: hearing
timeFrame: six month
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06730997: Clinicopathological Features of Renal Cell Carcinoma in Young Patients
Official title: Clinicopathological Features of Renal Cell Carcinoma in Young Patients and it's Influence on the Survival Outcome
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Clinicopathologic Characters of Renal Cell Carcinoma in Young Patients
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2024-12-12
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients with renal cell carcinoma 40 years or younger at Radiation Oncology Department, South Egypt Cancer Institute, clinical oncology Assuit University at the period from 2015 to 2022

Brief summary: Analysis of Clinicopathologic Characters of Renal Cell Carcinoma in Young Patients and their influence on the survival outcomes

Detailed description: Worldwide, RCC accounts for 2-3% of All adult malignancies and the 8th most commonly diagnosed primary cancer among all adults.

Representing 3rd place among urinary system tumors. Most of RCC occurs in old age while about 7% occurs in younger adults below 40 years.

Recently the published data about the tumor Clinco-pathological features, treatment response and outcomes were different in young adults than older patients, where some data showed favorable features and survivals, while other showed negative ones.

Eligibility criteria: Inclusion Criteria:

* Age \< 40 years

  * Patients proven to have RCC
  * Patients eligible to receive treatment

Exclusion Criteria:

* Second malignancy.

Primary outcomes:
measure: Analysis of Clinicopathologic Characters of Renal Cell Carcinoma in Young Patients and their influence on the survival outcomes
timeFrame: Analysis of Clinicopathologic Characters of Renal Cell Carcinoma in Young Patient in period from 2010 -2024
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Lipworth L, Tarone RE, McLaughlin JK. The epidemiology of renal cell carcinoma. J Urol. 2006 Dec;176(6 Pt 1):2353-8. doi: 10.1016/j.juro.2006.07.130.
citation: Suh JH, Oak T, Ro JY, Truong LD, Ayala AG, Shen SS. Clinicopathologic features of renal cell carcinoma in young adults: a comparison study with renal cell carcinoma in older patients. Int J Clin Exp Pathol. 2009;2(5):489-93. Epub 2009 Jan 30.
citation: Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. Eur Urol. 2016 Jul;70(1):93-105. doi: 10.1016/j.eururo.2016.02.029. Epub 2016 Feb 28.
Clinical trial NCT01475097: Comparing Patient Comfort and Safety Between Iodixanol and Iopamidol in Patients Undergoing Peripheral Arteriography
Official title: A Phase 4 Randomized, Double-blind Study Comparing Patient Comfort and Safety Between Iodixanol 320 mg I/mL and Iopamidol 370 mg I/mL in Patients Undergoing Peripheral Arteriography
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Drug Safety
Keywords: AE - Adverse event
Arteriography
IA - Intra-arterial
IOCM - Iso-Osmolar Contrast Medium
LOCM - Low-Osmolar Contrast Medium
Patient Comfort
Body Image Disturbance
Patient
Lead sponsor: GE Healthcare
Sponsor class: INDUSTRY
Collaborators: name: i3 Statprobe
First posted: 2011-11-21
Enrollment: 255
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: The purpose of this study is to evaluate and compare overall patient comfort profile between an Iso-osmolar contrast media (IOCM), iodixanol 320 mg I/mL, and a Low-osmolar contrast media (LOCM), iopamidol 370 mg I/mL in patients undergoing arteriography of peripheral arteries.


Eligibility criteria: Inclusion Criteria:

* The subject is over 18 years old.
* Subjects are referred to undergo a peripheral arteriography as part of their routine clinical care.

Exclusion Criteria:

* The subject has known allergies to iodine or any prior history of adverse reaction to iodinated CM.
* The subject received another administration of CM within 24 hours prior to baseline or is scheduled to receive one within the 24 hour follow-up period.
* The subject is pregnant or lactating.
* The subject is taking metformin (e.g., Glucophage®) but is not willing or unable to discontinue at the time of the study procedure.
* The subject manifests thyrotoxicosis or is on dialysis.

Primary outcomes:
measure: Subjects Experiencing Discomfort When Undergoing Peripheral Arteriography
timeFrame: Within 10 minutes post contrast administration.
Secondary outcomes:
measure: Comparison of Overall Image Quality Between Iodixanol and Iopamidol in Patients Undergoing Peripheral Arteriography.
timeFrame: Within 10 minutes post contrast administration.
Other outcomes:
Locations:
city: Princeton
country: United States
facility: GE Healthcare
state: New Jersey
Study officials:
affiliation: GE Healthcare
name: Lauren Lim, PharmD
role: STUDY_DIRECTOR
References:
Clinical trial NCT04084197: A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HIP1801 in Healthy Male Subjects.
Official title: An Open-label, Randomized, Single-dose Crossover Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HIP1801 in Healthy Male Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Lead sponsor: Hanmi Pharmaceutical Company Limited
Sponsor class: INDUSTRY
First posted: 2019-09-10
Enrollment: 61
Sex: MALE
Minimum age (years): 19
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: An open-label, randomized, single-dose crossover study to evaluate the pharmacokinetics, safety and tolerability of HIP1801 in healthy male subjects.


Eligibility criteria: Inclusion Criteria:

1. Age 19\~45 years in healthy male volunteers
2. BMI is more than 18.5 kg/m\^2 , no more than 29.9 kg/m\^2
3. Subjects who have ability to comprehend the objectives, contents of study and property of study drug before participating in trial and have willingness to sign of informed consent in writing

Exclusion Criteria:

1. Presence of medical history or a concurrent disease that may interfere with treatment and safety assessment or completion of this clinical study, including clinically significant disorders in digestive system, neuropsychiatric system, endocrine system, liver, cardiovascular system
2. Subjects who judged ineligible by the investigator

Primary outcomes:
measure: Cmax of Tamsulosin
timeFrame: pre-dose(0 hour), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48 hour
measure: AUClast of Tamsulosin
timeFrame: pre-dose(0 hour), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48 hour
Secondary outcomes:
measure: AUCinf of Tamsulosin
timeFrame: pre-dose(0 hour), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48 hour
measure: Tmax of Tamsulosin
timeFrame: pre-dose(0 hour), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48 hour
measure: t1/2 of Tamsulosin
timeFrame: pre-dose(0 hour), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48 hour
measure: CL/F of Tamsulosin
timeFrame: pre-dose(0 hour), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48 hour
measure: Vd/F of Tamsulosin
timeFrame: pre-dose(0 hour), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48 hour
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Korea University Anam Hospital
Study officials:
References:
Clinical trial NCT06710483: A Pilot Project to Facilitate Dental Care and Reduce Barriers For Youth With Disabilities
Official title: Do Telehealth Dental Interviews Facilitate in Person Clinical Visits for Patients With Complex Medical Needs?
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Intellectual Disability, Variable
Keywords: Intellectual and developmental disabilities
Telehealth interview
Pediatric dental care
Pre-Dental Care Telehealth Visit
Lead sponsor: Boston University
Sponsor class: OTHER
Collaborators: name: Deborah Munroe Noonan Memorial Research Fund
First posted: 2024-11-29
Enrollment: 50
Sex: ALL
Minimum age (years): 12
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This randomized clinical trial is an innovative pilot project to determine the acceptance and impact of telehealth visits on youth with intellectual and developmental disabilities (IDD), their caregivers, and dentists. The impact of the telehealth visit will be assessed by: 1) determining if the intervention group was more likely to achieve the set goals and 2) Likert scaled surveys of satisfaction of caregivers and dentists. Qualitative data will be collected to inform improvement on clinical interviews by the dentist.


Eligibility criteria: Inclusion Criteria:

* Have an appointment for a routine check up at the Pediatric Clinic or Pediatric Health Center at the Boston University Goldman School of Dental Medicine
* Diagnosis of Intellectual or developmental disability (IDD)
* Have a caregiver who is willing to participate in the study
* Have a dental provider who is willing to participate in the study
* English speaking

Exclusion Criteria:

* None

Primary outcomes:
measure: Number of participants who successfully completed the dental visit goal
timeFrame: within 1 week of the dental visit
Secondary outcomes:
measure: Caregiver satisfaction
timeFrame: within 1 week of the dental visit
measure: Dentist satisfaction
timeFrame: within 1 week of the dental visit
Other outcomes:
Locations:
city: Boston
country: United States
facility: Goldman School of Dental Medicine
state: Massachusetts
Study officials:
affiliation: Goldman School of Dental Medicine
name: Keri Discepolo, DDS MPH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01966783: Budesonide vs. Mesalazine vs. Budesonide/Mesalazine Suppository Combination Therapy in Acute Ulcerative Proctitis
Official title: Randomized, Double-blind, Multicentre Study to Compare the Efficacy and Safety of Budesonide Versus Mesalazine Suppository Versus a Combination Therapy of Budesonide/Mesalazine Suppositories in Patients With Acute Ulcerative Proctitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Proctitis
Lead sponsor: Dr. Falk Pharma GmbH
Sponsor class: INDUSTRY
First posted: 2013-10-22
Enrollment: 320
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to investigate the efficacy and safety of budesonide suppository for the treatment of acute ulcerative proctitis.


Eligibility criteria: Inclusion Criteria:

* Active ulcerative proctitis
* Diagnosis confirmed by endoscopy
* Established disease or new diagnosis

Exclusion Criteria:

* Crohn's disease, indeterminate colitis, ischemic colitis, radiation colitis, diverticular assoc. colitis, microscopic colitis
* Presence of proctitis of a different origin
* Prior bowel resection
* Presence of symptomatic organic disease of the gastrointestinal tract
* Asthma, tuberculosis, cardiovascular disease, diabetes mellitus, osteoporosis, active peptic ulcer disease, glaucoma, cataract, infection if careful medical monitoring is not ensured
* Local intestinal infection
* Abnormal hepatic or renal function
* Oral/rectal/intravenous corticosteroids therapy
* Existing or intended pregnancy or breast-feeding
* Participation in another clinical trial within the last 30 days, simultaneous participation in another clinical trial, or previous participation in this trial

Primary outcomes:
measure: Resolution of clinical symptoms
timeFrame: 8 weeks
Secondary outcomes:
measure: Rate of clinical and endoscopic remission
timeFrame: 8 weeks
measure: Rate of improvement
timeFrame: 8 weeks
measure: Rate of patients with clinical remission
timeFrame: 8 weeks
measure: Rate of patients with endoscopic remission
timeFrame: 8 weeks
Other outcomes:
Locations:
city: Berlin
country: Germany
facility: Charité-Campus Benjamin Franklin Universitätsmedizin Berlin
city: Cologne
country: Germany
facility: Evang. Krankenhaus Kalk, Medical Department
Study officials:
affiliation: Evang. Krankenhaus Kalk, Medical Department
name: Wolfgang Kruis, Professor
role: PRINCIPAL_INVESTIGATOR
affiliation: Charité-Campus Benjamin Franklin Universitätsmedizin Berlin
name: Britta Siegmund, Professor
role: PRINCIPAL_INVESTIGATOR
References:
citation: Kruis W, Neshta V, Pesegova M, Alekseeva O, Andreev P, Datsenko O, Levchenko O, Abdulkhakov S, Lozynskyy Y, Mostovoy Y, Soloviev K, Dorofeyev AE, Vieth M, Stiess M, Greinwald R, Mohrbacher R, Siegmund B. Budesonide Suppositories Are Effective and Safe for Treating Acute Ulcerative Proctitis. Clin Gastroenterol Hepatol. 2019 Jan;17(1):98-106.e4. doi: 10.1016/j.cgh.2018.04.027. Epub 2018 Apr 24.